Last reviewed · How we verify
Artra
At a glance
| Generic name | Artra |
|---|---|
| Sponsor | NPO Petrovax |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A 16-week Clinical Study Investigating a Dark Spot Corrector Serum in Women With Moderate Discrete Hyperpigmentation (NA)
- Comparison of Efficacy of Metformin Gel 30% vs Triple Combination Cream (Hydroquinone 4%, Flucinolone Acetonide 0.01%, Tretinoin 0.025%) in Treatment of Melasma in Tertiary Care Hospital Karachi (NA)
- Azelaic Acid 20% vs Hydroquinone 4% in Epidermal Melasma (NA)
- Fractionated 1927nm Laser for Hyperpigmentation in Fitzpatrick Skin Phototypes V and VI (NA)
- Prospective Evaluation of Topical Almond Oil vs Hydroquinone (PHASE4)
- COMPARISON OF A COSMETIC SERUM AND 4% HYDROQUINONE FOR TREATING MELASMA OVER 84 DAYS (NA)
- Efficacy and Safety of a Combined Serum Containing Melasyl™, 10% Niacinamide, Hyaluronic Acid, and HEPES (NA)
- A Study to Assess Efficacy of Supporting Properties and Safety of ARTNEO in Patients With Knee Osteoarthritis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Artra CI brief — competitive landscape report
- Artra updates RSS · CI watch RSS
- NPO Petrovax portfolio CI